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Abstract
Purpose/Objective(s)
Optimal treatment for locally advanced rectal cancer (LARC) with distant metastasis
remains elusive. We aimed to evaluate upfront systemic chemotherapy and short-course
radiotherapy (RT) followed by delayed surgery for such patients, and to identify favorable
prognostic factors.
Materials/Methods
We retrospectively reviewed 50 LARC patients (cT4 or cT3, <2 mm from the mesorectal fas-
cia) with synchronous metastatic disease. The primary endpoint was progression-free sur-
vival (PFS). The secondary endpoints were overall survival, treatment-related toxicity, and
compliance. We considered P values <0.05 significant.
Results
At 22 months median follow-up, the median PFS time was 16 months and the 2-year PFS
rate was 34.8%. Thirty-five patients who received radical surgery for primary and metastatic
tumors were designated the curable group. Six patients with clinical complete response
(ypCR) of metastases who underwent radical surgery for only the primary tumor were clas-
sified as potentially curable. Nine patients who received no radical surgery (3 received palli-
ative surgery) were deemed the palliative group. The ypCR rate among surgery patients
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was 13.6%. PFS rates for the curable or potentially curable groups were significantly longer
than that of the palliative group (P<0.001). On multivariate analysis, solitary organ metasta-
sis and R0 status were independent prognostic factors for PFS.
Conclusions
These findings demonstrated that a strong possibility that upfront chemotherapy and short-
course RT with delayed surgery are an effective alternative treatment for LARC with poten-
tially resectable distant metastasis, owing to achievement of pathologic down-staging, R0
resection, and favorable compliance and toxicity, despite the long treatment duration.
Introduction
In locally advanced rectal cancer (LARC), mesorectal fascia (MRF) involvement is a significant
prognostic factor influencing local recurrence and survival rates [1,2]. Preoperative long-course
concurrent chemoradiation (CCRT) followed by TME is widely accepted as a standard treat-
ment scheme for LARC [3,4]. A Dutch TME trial demonstrated that preoperative short-course
radiotherapy (RT) followed by immediate surgery reduced local recurrence, but did not benefit
patients with positive circumferential resection margins [5,6]. A Polish trial also demonstrated
that conventional CCRT produced significantly more down-staging than short-course RT fol-
lowed by immediate surgery despite no difference in survival and late toxicity [7]. Furthermore,
down-staging has been recently reported after delayed surgery [8,9].
Currently, stage IV LARC with potentially resectable distant metastasis is considered to be
distinct from stage IV disease with widespread distant metastasis. An effective treatment strat-
egy for patients with the former disease remains elusive. Several studies about LARC plus syn-
chronous distant metastases demonstrated that a curative approach including chemotherapy
and short-course RT followed by delayed surgery could be an effective and feasible treatment
[8,10]. Based on this, we conducted a phase II clinical trial (NCT01269229) [11], in which
patients with LARC and synchronous liver metastases were treated with upfront systemic che-
motherapy, short-course RT to the primary tumor and delayed surgery. The outcomes of this
approach were described previously [12]. However, the clinical significance of this treatment
scheme has not yet been established.
Hence, succceding our previous report [12], we retrospectively investigated our LARC
patients outside of a clinical trial NCT01269229 (off-protocol) to determine oncologic out-
comes and feasibility of the described therapeutic strategy. Furthermore, we aimed to identify
the favorable prognostic factors in primary metastatic LARC cancer patients who were enrolled
in this study.
Materials and Methods
Patient selection
This study was retrospective in design and received approval from the internal review board at
severance hospital (IRB No. 4-2015-0076). Medical records of 82 patients with stage IV LARC
with a limited number of metastatic lesions who underwent upfront chemotherapy and short-
course RT with delayed surgery between 2009 and 2014 were reviewed. Among 82 patients, 32
enrolled in the prospective study [11]; the rest of patients did not participated due to refusal or
ineligibility by lung, bone, or multiple organ metastases. These remaining 50 patients were
reviewed retrospectively in this study. The patient records and information were anonymized
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and de-identified prior to analysis. Patients had primary rectal tumors with pelvic organ
invasion (cT4) or mesorectal infiltration invasion with<2 mm distance from the MRF, and
potentially resectable distant metastases. Patients were diagnosed with biopsy-confirmed ade-
nocarcinoma as the primary rectal lesion. For the initial staging work up, digital rectal exami-
nation, sigmoidoscopy, pelvic computed tomography (CT), or MRI were performed to
evaluate local tumor extent and the involvement of the MRF. Chest radiography, CT scanning
of chest and abdomen, and positron emission tomography to identify distant metastasis were
also performed. Patients had good performance statuses and normal pretreatment hemato-
logic, renal, and hepatic functions.
Multidisciplinary team approach
Assessments and treatment approaches were determined at a multidisciplinary team confer-
ence in the Colorectal Cancer Center at our institution as described previously [12]; candidates
for upfront systemic chemotherapy and short-course RT with delayed surgery were selected
with the intention of performing R0 resection for TME after tumor regression and simulta-
neous complete resection of metastatic lesions. Resectability of the rectal and metastatic lesions
was assessed via imaging. All patients were administered 4 to 9 cycles (median 4 cycles) of
upfront systemic chemotherapy with a FOLFOX (5-fluorouracil/leucovorin/oxaliplatin combi-
nation) or FOLFIRI (5-fluorouracil/leucovorin/irinotecan combination) based regimen with or
without bevacizumab (Avastin) or cetuximab (Erbitux). RT of 25 Gy in five fractions was deliv-
ered for 5 consecutive work days 1 week following upfront chemotherapy. To allow for primary
tumor regression, the same chemotherapy regimen (median 4 cycles, range 0–8 cycles) was
performed between the end of RT and surgery for all patients except one. Chemotherapy was
administered 1 week after RT. Surgical resection was performed after evaluation of resectability
and treatment response at least 6 weeks after RT.
Short-course radiotherapy
The target volumes and RT short-course technique were described previously [12]. We defined
the gross tumor volume (GTV) as the primary tumor and any significant surrounding lymph-
adenopathy showing mesorectal infiltration. The clinical target volume (CTV) added a2 cm
margin to the GTV in superior and inferior directions, laterally encompassing the entire
mesorectum at the level of the GTV. A 5-field technique (anteriorposterior, right-lateral, right-
posterior-oblique, left-posterior-oblique, and left-lateral beams) covering the CTV with a 1 cm
margin was utilized. The CTV was covered within the 95% isodose line of the prescribed dose.
Tumor assessment, follow-up, response evaluation, and patterns of
failure
We performed staging work-up before short-course RT and immediately afterwards, prior to
surgery. The imaging studies were repeated to investigate the response and resectability. Patient
follow-up was performed at 1, 3, 6, and 12 months, with imaging undergone at 1, 6, and 12
months after surgery, and annually thereafter. Treatment-related toxicities were assessed at
every follow-up visit. We assessed acute treatment-related toxicities between RT and surgery.
Post-surgical complications were also evaluated. Toxicity was graded based on the Common
Toxicity Criteria, version 4.0, of the National Cancer Institute. We defined a complete response
(CR) as a 100% decrease in gross tumor size on clinical or radiological evaluation. Partial
response (PR) and progressive disease (PD) were defined as a50% decrease or>25% increase
in primary and metastatic gross tumors sizes or the detection of newly developed lesions,
respectively. Otherwise, cases were categorized as stable disease (SD). We assessed pathologic
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primary tumor response using Mandard’s classification[13]. Pathologic CR after upfront sys-
temic chemotherapy and short-course RT (ypCR) was specified as the absence of residual
tumor cells (Mandard grade I) in primary gross tumor. Good pathologic response was defined
as Mandard grade I or II (fibrosis with scattered tumor cells). We evaluated down-staging by
comparing pathologic T stage to T stage at diagnosis.
Statistical analysis
The primary endpoint of this study was progression-free survival (PFS). PFS was calculated
from the date of diagnosis to the date of disease progression, relapse, death from any cause, or
last follow-up. Secondary endpoints were overall actuarial survival (OS), treatment-related tox-
icity, and compliance. OS was calculated from the date of diagnosis to the date of death or last
follow-up. PFS and OS calculation was performed by the Kaplan–Meier method using the log-
rank test to estimate the statistical significance of the differences in survival. Cox’s proportional
hazards model was utilized for univariate and multivariate analyses to evaluate prognostic fac-
tors that influence PFS and OS. The hazard ratio (HR) is reported with 95% confidence inter-
vals (CIs). We compared the differences in nominal variables using Pearson’s χ2 test or Fisher's
exact test. The continuous variables were analyzed using the Mann-Whitney U test and t test.
We considered P values<0.05 significant. For all analyses, SPSS version 20.0.0 (IBM Corpora-
tion; Armonk, NY, USA) was used.
Results
Treatment groups based on the surgical treatment results after
preoperative treatment
After the completion of planned upfront chemotherapy and short-course RT, we evaluated
treatment response. Fifty patients showed PR or SD for the primary tumor. Among them, PD
for distant metastasis was shown in 7 patients who underwent no curative surgery. While 2
non-PD patients refused curative resection, 41 received radical surgery for their primary
tumors. Among these, 35 patients (70%) also underwent metastasectomy; the remaining 6
patients (12%) showed clinical CR for distant metastasis on follow-up imaging. We categorized
the 35 patients who underwent radical surgery for primary and distant metastatic tumors as
the curable group; the 6 patients who received radical surgery for only the primary tumor were
designated as the potentially curable group. The remaining 9 patients constituted as palliative
group. There were 3 palliative group patients who received palliative surgery due to primary
tumor bleeding. Hence, a total of 44 patients (88%) received rectal surgery. Low-anterior resec-
tion (LAR) was performed in 33 patients (66%), ultra-LAR with coloanal anastomosis for 8
patients (16%), and abdominoperineal resection for 3 patients (6%). A total of 33 patients
(66%) had R0 status of primary and metastatic tumors after surgery. A flowchart of upfront
chemotherapy and short-course RT with delayed surgery is depicted in Fig 1, and detailed
treatment characteristics are shown in S1 Table.
Patient characteristics based on the treatment groups
The patient characteristics at diagnosis are listed in Table 1. The palliative group had more
poorly differentiated adenocarcinoma (P = 0.04); additionally, this group had patients showing
extramural vascular invasion (P = 0.04). The potentially curable group showed more lung
metastases (P = 0.006). There were no differences in the remaining characteristics among the 3
groups.
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Pathologic reports for primary tumor, residual tumor status, and patterns
of failure
Among 44 patients who underwent surgery for rectal lesions, Mandard grade I (ypCR) was
shown in 6 patients (13.6%), II in 13 patients (29.6%), III in 16 patients (36.3%), IV in 7
patients (15.9%), and V in 2 patients (4.6%). Good pathologic response and down-staging were
observed in 19 (42.3%) patients and 20 (45.5%) patients, respectively. The pathology reports
are listed in Table 2. The surgical pathology characteristics, including Mandard grade I–II,
ypCR, down-staging, lymphovascular invasion, perineural invasion, and positive resection
margins were not different among the 3 groups (Table 3). Curable and potentially curable
groups achieved an R0 status of 80% and 83.3%, respectively. None of the palliative group
patients achieved an R0 status (P<0.001). Although local and regional failures were not differ-
ent among the three groups, more distant failure tended to occur in the palliative group
(88.9%; P = 0.07).
Fig 1. A flowchart depicting the timeline of upfront chemotherapy and short-course radiotherapy with delayed surgery at our institution.
doi:10.1371/journal.pone.0161475.g001
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Survival analysis and favorable prognostic factors
Median follow-up duration for surviving patients was 22 months (range, 9–59 months). Median
PFS was 16 months, and the 2-year PFS rate was 34.8%. The 2- and 5-year OS rates were 73.9%
and 55.1%, respectively. Kaplan-Meier curves demonstrated that PFS rates of the curable and
potentially curable groups were significantly longer than that of the palliative group (Fig 2A, cur-
able vs. potentially curable vs. palliative groups, median PFS 18 months vs. not reached vs. 11
months, P<0.001). Kaplan-Meier analysis also showed that the curable and potentially curable
groups showed longer OS than the palliative group (Fig 2B, curable vs. potentially curable vs. pal-
liative groups, median OS not reached vs. not reached vs. 24 months, P = 0.037).
Table 1. Patient characteristics.
Curable(n = 35) Potentially curable
(n = 6)
Palliative(n = 9)
Variables Groups n % n % n % P value
Age (years) <60 19 54.3% 3 50.0% 3 33.3% 0.56
60 16 45.7% 3 50.0% 6 66.7%
Sex Male 23 65.7% 5 83.3% 6 66.7% 0.8
Female 12 34.3% 1 16.7% 3 33.3%
ECOG PS 0 6 17.1% 0 0.0% 0 0.0% 0.4
1 29 82.9% 6 100.0% 9 100.0%
Differentiation Well 8 22.9% 0 0.0% 1 11.1% 0.04
Moderately 24 68.6% 3 50.0% 5 55.6%
Poorly 2 5.7% 1 16.0% 3 33.3%
Unspeciﬁed 1 2.9% 2 33.3% 0 0.0%
CEA Median (range) 12.42 (0.85–364.1) 3.4 (0.6–164.9) 12.79 (4.18–1203.8) 0.13
K-ras status Wild type 17 48.6% 2 33.3% 5 55.6% 0.16
Mutant 4 11.4% 0 0.0% 3 33.3%
Unknown 14 40.0% 4 66.7% 1 11.1%
Initial cT stage cT3 28 80.0% 4 66.7% 8 88.9% 0.74
cT4 7 20.0% 2 33.3% 1 11.1%
Initial cN stage cN0 1 2.9% 0 0.0% 0 0.0% <0.99
cN1 34 97.1% 6 100.0% 9 100.0%
Distance from AV Median (cm, range) 7.2 (2.7–12) 5.5 (3–10) 9 (6.5–13.4) 0.128
Mesorectal LNI Yes 33 94.3% 6 100.0% 9 100.0% <0.99
Lateral LNI Yes 15 42.9% 3 50.0% 5 55.6% 0.83
EMVI Yes 24 68.6% 3 50.0% 9 100.0% 0.04
Metastatic sites Liver 19 54.3% 1 16.7% 5 55.6% 0.3
Lung 8 22.9% 5 83.3% 5 55.6% 0.006
PAN region 14 40.0% 1 16.7% 2 22.2% 0.46
Others* 4 11.4% 2 33.3% 1 11.1% 0.35
No. of metastatic lesions Median (range) 4 (1–17) 4 (1–13) 6 (1–21) 0.48
3 17 48.6% 2 33.3% 3 33.3% 0.61
>3 18 51.4% 4 66.7% 6 66.7%
Distant metastasis Solitary 24 68.6% 3 50.0% 4 44.4% 0.35
Multiple 11 31.4% 3 50.0% 5 55.6%
*: Ovary, axillary & supraclavicular lymphatics
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status; CEA, Carcinoembryonic antigen; AV, anal verge; LNI, lymph node
involvement; EMVI, extramural vascular invasion; PAN, para-aortic nodal.
doi:10.1371/journal.pone.0161475.t001
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On univariate analysis of PFS with clinical prognostic factors, the number of metastatic
lesions (3 vs.>3), pattern of distant metastasis (solitary vs. multiple), residual tumor status
(R0 vs. R1–2), and good pathologic response in primary tumor (yes vs. no) were significantly
associated with PFS (Table 4). On multivariate analysis, the pattern of distant metastasis (soli-
tary vs. multiple) and residual tumor status (R0 vs. R1–2) were independent prognostic factors
that influenced PFS significantly. The number of metastatic lesions affected PFS with a statisti-
cal trend (P = 0.057). Residual tumor status (P = 0.002) and carcinoembryonic antigen
(P = 0.005) were significantly related to OS on univariate analysis (Table 4). The residual
tumor status (R0 vs. R1–2: HR, 0.12; 95% CI, 0.03–0.6; P = 0.01) was an independent signifi-
cant prognostic factor for OS.
Treatment-related toxicity and the compliance
Treatment-related toxicities are shown in Table 5. Upfront chemotherapy-related severe hema-
tologic and gastro-intestinal toxicities developed in 3 (6%) and 4 (8%) patients, respectively.
Upfront chemotherapy and short-course RT-related grade 3 diarrhea developed acutely in 17
patients (35%). However, after the completion of treatment, diarrhea resolved in all patients.
As for surgical complications, anastomotic leakage was observed in 7 patients (16%); 3 major
and 4 minor. Perineal infection occurred in 2 patients (5%). Upfront chemotherapy and short-
course RT with delayed surgery was considered tolerable.
Median treatment duration from diagnosis to surgery was 5.4 months (range, 1.7–9.0
months). Median time between completion of short-course RT and surgery was 3.3 months
(range, 0.3–4.4 months). Median hospitalization duration for patients who underwent surgery
was 11 days (range 6–91 days).
Discussion
While systemic combination chemotherapy is critical for rectal cancer with distant metastasis,
long-course RT is considered the appropriate treatment for LARC according to NCCN
Table 2. Pathology reports (n = 44).
Variables Groups n %
Mandard grade for primary tumor I 6 13.6%
II 13 29.6%
III 16 36.3%
IV 7 15.9%
V 2 4.6%
ypT stage ypT0 6 13.6%
ypT1 1 2.3%
ypT2 5 11.3%
ypT3 30 68.2%
ypT4 2 4.6%
ypN stage ypN0 20 45.5%
ypN1 10 22.7%
ypN2 14 31.8%
Down-staging Yes 20 45.5%
No 30 54.5%
Lymphovascular invasion Yes 9 20.5%
Perineural invasion Yes 3 6.8%
doi:10.1371/journal.pone.0161475.t002
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guideline [14]. However, long-course RT for LARC with distant metastasis has some problems
as follows: 1) the start of systemic combination chemotherapy is delayed; 2) long-course RT
could not be performed concurrently with systemic combination chemotherapy due to treat-
ment-related acute toxicity. Recently, some studies including T4 patients demonstrated that
short-course RT followed by delayed surgery could improve local control rates for LARC
patients [8,9,15]. So, we choose short-course RT and systemic combination chemotherapy to
control both local tumor and distant metastasis without severe acute toxicities.
The effect of systemic chemotherapy and short-course RT followed by delayed surgery for
rectal cancer diagnosed with distant metastasis has not been well established. A Dutch group
demonstrated that short-course RT and chemotherapy followed by surgery could be attractive
alternatives to traditional staged resection for rectal cancer with synchronous liver metastases,
based on the achievement of 15 months of disease-free survival, a 5-year OS of 38%, and tolera-
bility of treatment [16]. An open-label, single-arm phase II prospective clinical study recently
reported that short-course RT followed by combination chemotherapy including capecitabine
and oxaliplatin with bevacizumab and subsequent radical surgery could be a potentially cura-
tive treatment and was feasible for 50 rectal cancer patients of similar severity [10]. The rate of
R0 status, which was the primary endpoint of their study, was 72%; the 2-year OS and recur-
rence rate were 80% and 64%, respectively. Treatment-related deaths and grade 3–4 short-
course RT-induced toxicities did not develop. Our findings were comparable to those of previ-
ous studies, and we deduced that upfront systemic chemotherapy and short-course RT fol-
lowed by delayed surgery is an effective and feasible treatment for LARC with potentially
resectable distant metastasis.
While long-course CCRT followed by delayed surgery can induce tumor down-staging,
short-course RT followed by immediate surgery is not known to be effective for tumor regres-
sion despite no statistical difference of survival outcomes compared to long-course CCRT fol-
lowed by delayed surgery [17,18]. Several studies demonstrated that short-course RT followed
by delayed surgery could result in substantial tumor regression and down-staging for LARC
Table 3. Surgical pathology for primary tumor, residual tumor status, and patterns of failure based on treatment groups.
Curable Potentially curable Palliative
n (%) n (%) n (%) P value
Surgical pathology* (n = 44)
•Mandard grade I-II 15 (42.9) 3 (50.0) 1 (33.3) <0.99
• ypCR 5 (14.3) 1 (16.7) (0.0) 1
• Downstaging 14 (40.0) 5 (83.3) 1 (33.3) 0.118
• Lymphovascular invasion 8 (22.9) 0 (0.0) 1 (33.3) 0.17
• Perineural invasion 3 (8.6) 0 (0.0) 0 (0.0) 0.65
• Resection margin (+) 3 (8.6) 1 (16.7) 0 (0.0) 0.61
Residual tumor status
• R0 28 (80.0) 5 (83.3) 0 (0.0) <0.001
• R1 or R2 7 (20.0) 1 (16.7) 9 (100.0)
Patterns of failure
• Local failure 2 (5.7) 0 (0.0) 0 (0.0) <0.99
• Regional failure 1 (2.9) 0 (0.0) 0 (0.0) <0.99
• Distant failure 18 (51.4) 2 (33.3) 8 (88.9) 0.07
*: except 6 patients who underwent no rectal surgery
Abbreviation: ypCR, pathologic complete response after preoperative treatment.
doi:10.1371/journal.pone.0161475.t003
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patients [8,9,15]. However, other studies insisted that short-course RT followed by delayed sur-
gery did not increase tumor down-staging and showed poor pathologic responses compared to
long-course conventional CCRT [19,20]. The only prospective study of short-course RT fol-
lowed by delayed surgery for rectal cancer diagnosed with distant metastasis demonstrated that
patients had a ypCR rate of 26% and a down-staging rate of 47% [10]. Consistent with previous
studies, we showed a ypCR rate of 13.6% and a down-staging rate of 45.5%. We propose that
short-course RT with delayed surgery will induce substantial down-staging for patients with
MRF involvement.
Systemic chemotherapy has been a critical treatment for metastatic rectal cancer to manage
metastatic lesions and eradicate microscopic disease [14]. Several studies demonstrated that
systemic chemotherapy could help improve outcomes [21,22]. These studies also showed that
pathologic response to neoadjuvant chemotherapy would predict survival of patients with
resectable metastases from colorectal cancer [23,24]. In our study, 6 patients in the potentially
curable group showed clinical CR of distant metastasis after systemic chemotherapy alone,
resulting in an excellent survival outcome. Taken together, cumulative data confirm that sys-
temic chemotherapy is an essential treatment for enhancing survival rates of LARC patients
with synchronous metastatic disease.
There is great heterogeneity in rectal cancer patients diagnosed with distant metastases,
which can complicate treatment decisions. Because there are no clear criteria for selecting
Fig 2. Kaplan-Meier curves according to treatment groups. (a) The progression-free survival rates of the
curable (broken line) and potentially curable (line) groups were significantly longer than that of the palliative
group (dotted line). (b) The curable (broken line) and potentially curable (line) groups showed longer overall
survival than the palliative group (dotted line).
doi:10.1371/journal.pone.0161475.g002
Table 4. Stepwise uni- andmulti-variate analysis using cox regression model for progression-free and overall survival.
Progression-free survival Overall survival
Univariables Multivariable Univariables Multivariable
Variables p value HR (95% CI) p value p value HR (95% CI) p value
Age (continuous) 0.47 0.48
Gender (male vs. female) 1 0.88
ECOG performance (0 vs. 1) 0.23 0.52
Differentiation (others vs. poorly differentiated) 0.95 0.19
CEA (continuous) 0.11 0.005 1.002 (1–1.004) 0.03
K-ras mutation (others vs. K-ras mutation) 0.99 0.33
Clinical T stage (T3 vs. T4) 0.43 0.92
Distance from anal verge (cm) (continuous) 0.45 0.39
Extramural vascular invasion (no vs. yes) 0.27 0.51
Liver metastasis (no vs. yes) 0.26 0.7
Lung metastasis (no vs. yes) 0.61 0.88
PALN metastasis (no vs. yes) 0.51 0.48
No. of metastatic lesion (3 vs. >3) 0.006 0.42 (0.18–1.03) 0.057 0.34
Pattern of distant metastasis (solitary vs. multiple) 0.002 0.34 (0.15–0.75) 0.008 0.22
Residual tumor status (R0 vs. R1-2) 0.001 0.24 (0.1–0.56) 0.001 0.002 0.12 (0.03–0.6) 0.01
Good pathologic response in PT (Yes vs. no) 0.03 0.09
Downstaging (Yes vs. no) 0.32 0.19
Abbreviation: ECOG, Eastern Cooperative Oncology Group; CEA, Carcinoembryonic antigen; PALN, para-aortic lymph node; PT, primary tumor; HR,
hazard ratio; CI, conﬁdence interval.
doi:10.1371/journal.pone.0161475.t004
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patients to whom to apply this treatment strategy, it is important to elucidate the clinical fac-
tors that can identify patients who would benefit from it. Based on previous studies, one of the
most consistently reported factors is multiplicity of metastases. Many other studies demon-
strated that solitary or low numbers of metastasis showed a significantly better survival rate
than multiple metastases of the liver, lung, and other organs [25–30]. Our study also indicated
that multiplicity of metastasis was significantly associated with PFS. Therefore, we propose that
this treatment scheme should enhance survival for colorectal cancer patients with fewer meta-
static lesion or a solitary metastatic organ.
In our study, there were 9 patients (palliative group) who did not undergo surgery after pre-
operative treatments. While 3 patients were treated with palliative surgery because of severe
tumor bleeding, the remaining 6 patients had no severe pelvic symptoms including rectal
bleeding, pain, and obstruction. Recently, one prospective study described findings similar to
ours [31]. Of 40 patients, only 8 (20%) underwent palliative surgery because of local symptom-
atic progression. Although all patients had severe pelvic symptoms before RT, pelvic symptoms
were completely resolved during the whole course of the disease in 30% of patients, and signifi-
cant symptomatic improvement was observed in 35% of patients. Our results suggest that
upfront systemic chemotherapy and short-course RT could help relieve pelvic symptoms
caused by rectal cancer.
There were several limitations to consider. First, since this study is retrospective, patient
characteristics were heterogeneous; furthermore, targeted therapeutic drugs were not adminis-
tered to 38 patients (76%). Especially, this study included various sites of metastasis. The het-
erogeneity of metastatic organ could induce the different effects of this treatments strategy on
the prognosis, despite multivariate analysis including several factors related to metastasis. So,
further study involving the large number of homogenous patients would be needed. Second,
the number of patients in this study was small. Third, there are controversies regarding the def-
inition of resectability for metastatic lesions. At our institution, resectability was determined
Table 5. Treatment-related toxicity.
n %
Chemotherapy-related grage 3 toxicity
• Hematologic 3 6%
•GI (nausea/vomiting/mucositis) 4 8%
• Neuropathy 0 0%
•Gerenal weakness 0 0%
Chemotherapy and SCRT-related grage 3 toxicity
• Diarrhea 17 35%
Surgery-related toxicity
• Anastomotic leakage 7 16%
Major 3 7%
Primary repair & I/D 3 7%
Loop ileostomy 2 5%
Minor 4 9%
Transanal reinforcement suture 2 5%
Pigtail insertion 1 2%
Observation (Asymptomatic) 1 2%
• Perineal infection 2 5%
• Chyle leakage 1 2%
Abbreviation: SCRT, short-course radiotherapy.
doi:10.1371/journal.pone.0161475.t005
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based on the extent of metastatic disease and functional reserve of the non-metastatic organ
region. Fourth, because all of the stage IV LARC patients with limited number of metastatic
lesions between 2009 and 2014 underwent upfront systemic chemotherapy and short-course
RT with delayed surgery, we could not compare the chemotherapy only, or chemotherapy and
long course RT with the treatment scheme of this study. This randomization study would be
warranted to confirm role of pelvic radiotherapy in metastatic setting. So, further study would
be needed. Despite these limitations, we consider our findings reliable.
Conclusions
In conclusion, our data demonstrate a strong possibility that upfront chemotherapy and short-
course RT with delayed surgery are an effective alternative treatment for LARC with potentially
resectable distant metastasis, owing to achievement of pathologic down-staging, R0 resection,
and favorable compliance and toxicity, despite the long treatment duration.
Supporting Information
S1 Table. Treatment characteristics. The detailed treatment characteristics are shown.
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